This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. VRCA, RLMD, FGEN, TPST, LTRN, RNXT, NBRV, CALC, ATHE, and AADIShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Verrica Pharmaceuticals (VRCA), Relmada Therapeutics (RLMD), FibroGen (FGEN), Tempest Therapeutics (TPST), Lantern Pharma (LTRN), RenovoRx (RNXT), Nabriva Therapeutics (NBRV), CalciMedica (CALC), Alterity Therapeutics (ATHE), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors Verrica Pharmaceuticals Relmada Therapeutics FibroGen Tempest Therapeutics Lantern Pharma RenovoRx Nabriva Therapeutics CalciMedica Alterity Therapeutics Aadi Bioscience Verrica Pharmaceuticals (NASDAQ:VRCA) and TenX Keane Acquisition (NASDAQ:TENK) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Which has better earnings & valuation, VRCA or TENK? TenX Keane Acquisition has lower revenue, but higher earnings than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M6.38-$76.58M-$8.28-0.62TenX Keane AcquisitionN/AN/AN/AN/AN/A Does the media refer more to VRCA or TENK? In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 2 mentions for Verrica Pharmaceuticals and 0 mentions for TenX Keane Acquisition. Verrica Pharmaceuticals' average media sentiment score of 0.58 beat TenX Keane Acquisition's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Verrica Pharmaceuticals Positive TenX Keane Acquisition Neutral Do analysts rate VRCA or TENK? Verrica Pharmaceuticals currently has a consensus target price of $80.00, suggesting a potential upside of 1,465.56%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in VRCA or TENK? 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 70.5% of TenX Keane Acquisition shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 22.9% of TenX Keane Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is VRCA or TENK more profitable? Company Net Margins Return on Equity Return on Assets Verrica PharmaceuticalsN/A N/A -115.48% TenX Keane Acquisition N/A N/A N/A SummaryVerrica Pharmaceuticals beats TenX Keane Acquisition on 7 of the 9 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$12.51M$248.59M$2.38B$9.94BDividend YieldN/A3.17%13.79%4.53%P/E RatioN/A0.1725.0026.11Price / SalesN/A490.3217,615.47121.74Price / CashN/A123.7059.9829.11Price / BookN/A7.883.256.09Net IncomeN/A-$11.59M-$445.27M$266.19M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$1.88+0.5%N/A+6.2%$12.51MN/A0.00N/AGap DownHigh Trading VolumeVRCAVerrica Pharmaceuticals4.0534 of 5 stars$5.16-1.3%$80.00+1,450.4%-73.2%$49.40M$7.57M-0.6240RLMDRelmada Therapeutics3.9454 of 5 stars$1.37-6.8%$5.00+265.0%-31.3%$48.79MN/A-0.6210Gap DownFGENFibroGen3.9595 of 5 stars$11.31-5.4%$43.00+280.2%+24.1%$48.37M$29.62M-29.76570TPSTTempest Therapeutics2.0413 of 5 stars$10.03-4.5%$30.00+199.1%-31.8%$46.62MN/A-0.6920Positive NewsLTRNLantern Pharma1.6393 of 5 stars$4.20-2.1%$25.00+495.2%+26.0%$46.33MN/A-2.3620Positive NewsRNXTRenovoRx2.1273 of 5 stars$1.19-4.8%$7.50+530.3%+21.6%$45.81M$40K-3.136Negative NewsShort Interest ↑Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070CALCCalciMedica3.2465 of 5 stars$3.17-1.6%$16.00+404.7%-41.9%$44.99MN/A-1.9830Positive NewsShort Interest ↓ATHEAlterity Therapeutics2.3486 of 5 stars$4.74-8.2%$12.00+153.4%N/A$44.96MN/A0.0010Short Interest ↓AADIAadi BioscienceN/A$1.81-0.5%N/A-0.5%$44.70M$25.07M-0.7940 Related Companies and Tools Related Companies VRCA Alternatives RLMD Alternatives FGEN Alternatives TPST Alternatives LTRN Alternatives RNXT Alternatives NBRV Alternatives CALC Alternatives ATHE Alternatives AADI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 9/8/2025 by MarketBeat.com Staff From Our PartnersThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TENK Stock Alerts